Research programme: severe pain therapeutic - RelevareAlternative Names: CNSB 004; Leconotide - Relevare
Latest Information Update: 01 Sep 2015
At a glance
- Originator CNSBio
- Developer Relevare Pharmaceuticals
- Class Non-opioid analgesics; Peptides; Venoms
- Mechanism of Action N-type calcium channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 07 Oct 2008 Preclinical trials in Pain in Australia (IV)